Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
In this study, individuals without hepatitis C infection who are on the kidney transplant
waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be
treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100
mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant
procedure and continued for 12 weeks post-renal transplant.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Elbasvir-grazoprevir drug combination Grazoprevir Ribavirin Sofosbuvir